脑转移是恶性肿瘤进展中非常剧烈的事件，往往预示着更高的死亡率。代谢改变是癌症的特征，癌症进展中脂质代谢重组的面纱正逐渐揭开。在这项工作中，我们分别回顾了与来自肺部、乳腺和皮肤黑色素瘤的脑转移相关的脂质表达和活性变化的临床和基础研究。发现了脂质代谢重编程在恶性肿瘤脑转移的发展中的新角色，并评估了其作为治疗靶点的潜力。从1990年到2022年，我们在PubMed、Embase、Scopus和www.ClinicalTrials.gov等数据库中搜索了发表的文献和临床研究。脑转移中的脂质代谢重编程涉及低脂质供应环境中的新脂质合成、脂质摄取和贮存的调节，脑肿瘤与脑微环境之间的代谢相互作用以及膜脂质重塑，此外还作为信号转导的第二信使。尽管一些脂质代谢调节剂在临床前模型中效果显著，但从实验室到临床仍然有很长的路要走。通过药物调节的代谢靶点和膳食干预，这一研究领域为脑转移的器官靶向治疗提供了保证。

Brain metastasis is a highly traumatic event in the progression of malignant tumors, often symbolizing higher mortality. Metabolic alterations are hallmarks of cancer, and the mask of lipid metabolic program rearrangement in cancer progression is gradually being unraveled.In this work, we reviewed clinical and fundamental studies related to lipid expression and activity changes in brain metastases originating from lung, breast, and cutaneous melanomas, respectively. Novel roles of lipid metabolic reprogramming in the development of brain metastasis from malignant tumors were identified and its potential as a therapeutic target was evaluated. Published literature and clinical studies in databases consisting of PubMed, Embase, Scopus and www.ClinicalTrials.gov from 1990 to 2022 were searched.Lipid metabolic reprogramming in brain metastasis is involved in de novo lipid synthesis within low lipid availability environments, regulation of lipid uptake and storage, metabolic interactions between brain tumors and the brain microenvironment, and membrane lipid remodeling, in addition to being a second messenger for signal transduction. Although some lipid metabolism modulators work efficiently in preclinical models, there is still a long way to go from laboratory to clinic. This area of research holds assurance for the organ-targeted treatment of brain metastases through drug-regulated metabolic targets and dietary interventions.